Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Preoperative Embolization Linked to Relapse-Free Survival in Meningioma
2.
Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.
3.
Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia
4.
Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.
5.
Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024
1.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
4.
Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment
5.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
Thromboprophylaxis In Medical Settings
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge